A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), marking the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada!
Granted under Health Canada’s Priority Review process, this approval represents its potential to significantly impact the lives of those affected by the debilitating disease. This is a landmark moment for families and clinicians, advancing the mission to raise the standard of care, improve access to therapies, and support those living with Duchenne across the country.
- AGAMREE® is approved for boys aged 4 years and older, with no upper age limit.
- The AGAMREE® Patient Support Program opens for enrollment on October 10, 2025.
“Given the significant unmet need of individuals with DMD, I am pleased that AGAMREE® has received priority review and is now approved by Health Canada. As AGAMREE® has no impact on linear growth and showed favourable changes in serum bone turnover biomarkers, it provides families with a viable treatment option compared to other corticosteroids.”
— Dr. Jean Mah, Director of the Pediatric Neuromuscular Program at the Alberta Children’s Hospital and NMD4C Investigator
“For too long, Canadian families have watched treatment advances unfold elsewhere while waiting for options here at home. With this approval, a new era of innovative therapies and treatments for Duchenne begins. This milestone is cause for celebration, while the continued focus remains on ensuring that AGAMREE® is not only approved, but also reimbursed and accessible to every Canadian who needs it.”
— Dr. Homira Osman, VP of Research & Public Policy, Muscular Dystrophy Canada & NMD4C Steering Committee Co-Chair
“This is an exciting day for Canadians and many Duchenne parents join in celebrating the very first treatment approved in Canada. It is thanks to the collaborative efforts of all who have been involved in bringing this treatment to fruition. The hope is that this is the first of many treatment options that will become available to Canadians living with Duchenne.”
— Nicola Worsfold, Executive Director, Defeat Duchenne Canada
This achievement is a testament to the power of collaboration among researchers, clinicians, families, and advocacy organizations. It reflects our collective commitment to raising the standard of care, improving access to therapies, and building research capacity across Canada.
For more details on AGAMREE®
Read the Full Announcement
Read next...
Advancing Neuromuscular Research: 2025 NMD4C Publications
Our network continues to grow, collaborate, and push the field forward, and these 2025 publications highlight the impact our community is making together
2026 NMD4C Application & Nomination Deadlines
As we start the new year, three important NMD4C opportunities are approaching their deadlines. Members are invited to nominate a researcher or publication for the Annual NMD4C Awards, apply to join the Basic Science Trainee Committee (BSTC), and apply to attend the 2026 NMD4C Basic Research Summer School, taking place June 8–10 under the leadership of Dr. Mireille Khacho. Registration for the summer school is free, with travel and accommodations covered for non‑local trainees.
Announcing the 2026 Neuromuscular Postdoctoral Fellowship Funding Recipients!
Together with Muscular Dystrophy Canada (MDC), we’re excited to share that the 2026 Neuromuscular Postdoctoral Research Fellows have been awarded! This year’s competition provided salary support for two exceptional early‑career scientists to pursue postdoctoral research in Canadian laboratories dedicated to advancing neuromuscular research. Successful applicants will receive $40,000 in funding over a one-year period.